Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials
Pharmacology, Toxicology and Pharmaceutical Science
5
16%
Medicine and Dentistry
3
10%
Biochemistry, Genetics and Molecular Biology
1
3%
Immunology and Microbiology
1
3%
Nursing and Health Professions
1
3%
Other
0
0%
Unknown
20
65%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2021.
All research outputs
#15,686,478
of 23,310,485 outputs
Outputs from BMC Cancer
#4,205
of 8,441 outputs
Outputs of similar age
#283,977
of 510,399 outputs
Outputs of similar age from BMC Cancer
#86
of 223 outputs
Altmetric has tracked 23,310,485 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,441 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 510,399 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 223 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
